CER Daily Newsfeed

Value Viewpoint: October 17, 2025

(10/17, Kimberly Westrich, LinkedIn) comments “...A new article published in Value in Health explores the question of whether early-stage NIH funding that supports drug development should directly influence how new drugs are priced...Past efforts to impose ‘reasonable pricing’ discouraged collaboration, and new proposals such as march-in rights risk similar harm. Instead, the authors suggest preserving innovation requires stable pricing rules, value-based assessments, strong IP protections, and coverage reforms to improve affordability without weakening incentives for industry to translate basic research into treatments.” Full

Deuruxolitinib Shows Greatest Short-Term Efficacy Among JAKis for Severe Alopecia Areata

(10/17, Tim Smith, HCPLive) reports “Deuruxolitinib 8 mg twice daily shows the greatest short-term efficacy among approved oral Janus-Kinase (JAK)-inhibitors for severe alopecia areata, new findings suggest...‘This focused research fills a critical knowledge gap in the literature by comparing the relative efficacy of oral JAKIs using advanced Bayesian statistical techniques and anchor placebo-controlled data,’ the investigators wrote.” Full

Senate Health Committee To Revisit 340B Issues, Solutions

(10/17, Gabrielle Wanneh, Inside Health Policy) reports “Months after unveiling the findings of a years-long investigation of the growth of the 340B drug discount program and the impact certain operational issues and covered entity practices have had on patients, the Senate health committee is due to revisit ongoing concerns with the program next week. The press office for the committee did not respond to an inquiry from Inside Health Policy on whether committee chair Bill Cassidy (R-LA) will introduce long-awaited 340B reform legislation.” Subscription Required

European Commission Adopts Final Implementing Regulation for Joint Clinical Assessments under the EU HTA Framework

(10/20, Katie McCool, The Evidence Base) reports “...According to the European Commission, the regulation ‘provides detailed procedural rules for the joint clinical assessments,’ covering cooperation between the Member State Coordination Group on Health Technology Assessment and the European Commission with notified bodies and expert panels...Commenting on the new regulation, Natalia Eitel of Vintura noted that it ‘provides detailed procedural rules for the joint clinical assessments,’ including provisions for cooperation with notified bodies and expert panels, stakeholder engagement, and standardized reporting formats.” Full